Thus, early use of mTORi might be prudent to avoid the development of calcineurin inhibitor toxicity and CAN and to derive the maximum benefit with regard to viral infections, cardiovascular events, and malignant tumors5, although we did not evaluate the effect of Rapa in combination with a CNI on the VEGF network. Here, TRERF1 is linked to viral infectious disease.